Jason Bednar

Karen confirmed $4 million of refunds received against about $27 million potentially available ($24 million eligible under phase one and two), and said restructuring costs are for shutting down and consolidating old facilities, with benefits built into the new facility.

Dan said the destocking trajectory is playing out as modeled, expecting improvement by the end of Q2 and material improvement by Q3.

Karen explained the withholding tax creates an incremental hurdle for buybacks, making larger amounts uneconomical when factoring in lost interest and potential borrowing costs. $200-300M is the measured approach.

Dan emphasized improved supply chain resilience with reduced single-source dependency and strategic inventory buffers. Karen noted raw materials are less than 20% of COGS with measured oil-impact assumptions.

Dan said macros are not negative and no material market changes are visible. Planning cycle underway with formal FY27 guidance coming next quarter. Did not see downside risks to growth algorithm.

Karen cited Q4 timing risk on cash collections, heavy CapEx quarter, and weather impacts as reasons for maintaining $850M FCF guide despite strong 9-month results. Acknowledged conservatism.

Dan rank-ordered Healthcare growth: service highest, consumables second, capital growing but timing-dependent. Noted $400M+ Healthcare capital backlog with strong order rates.

Karen attributed strong H1 FCF to pulled-forward earnings, faster collections on late FY25 shipments, working capital improvements, and acknowledged some conservatism in full-year guide.

Dan noted continued small M&A activity while looking for larger opportunities. Mike explained cash will build as no prepayable debt remains until 2027.

Dan attributed order strength to STERIS's portfolio positioning with large healthcare customers seeking partnership-type vendors.

Mike confirmed the $30M is a net number (gross is significantly higher), and $200M of buybacks were front-loaded in FY25. Tariff impact expected equally throughout the year.

Dan confirmed tariff exposure is roughly evenly split between China-related and the 10% global tariff, totaling $30M net of mitigation.

Dan confirmed the second case was pushed to summer to accommodate the May retrial of the first case. No additional cases have been added.

Mike highlighted favorable volume, mix, and price across both segments and noted healthcare is seeing productivity improvements for the first time all year.

Dan firmly declined to discuss EO litigation details despite multiple follow-ups, referring all questions to 10-Q disclosures.

Dan confirmed the AST outlook revision is purely volume-driven, not pricing-related, and characterized it as a conservative adjustment based on run rate trends.

Al explained EMEA's subscription/direct-to-consumer model prevents the inventory swings seen in the U.S., so a comparable destock is not needed there.

Brian said salesforce additions are a near-term margin headwind for longer-term benefit but declined to give 2027 guidance until December.

Brian defended the unchanged guide as prudent, citing H2 FX headwinds and a modest CooperVision revenue reduction rather than added conservatism.

Industry pricing dynamics calming and ability to absorb further increases. Management responded with context on this topic.

New fit activity trends vs peers in dailies and monthlies. Management responded with context on this topic.

Board chair transition rationale and selection of Colleen Jay. Management responded with context on this topic.

Share repurchase not assumed in EPS guidance despite 2/3 FCF allocation. Management responded with context on this topic.

Clarity drawdown unprecedented in trade-up cycles. Management responded with context on this topic.

Industry pricing moderating and fiscal 2026 outlook at ~1%. Management responded with context on this topic.

Disconnect between best month in April and lowered CVI guidance. Management responded with context on this topic.

MyDay MiSight launch planning, regulatory timeline and pricing strategy. Management responded with context on this topic.

Did timing of price increase communication affect Q4 buying patterns. Management responded with context on this topic.

Product pipeline and upcoming launches over next 12-18 months. Management responded with context on this topic.

Hogan said nothing is orthogonal to the review but named no specific expense lines, leaving scope undefined.

Morici confirmed the 2027 margin framing is inclusive of DirectFab, including its scale-up headwind.

Joe differentiated DSO vs retail dynamics: DSOs have recruitment/financing skills; retail doctors getting HFD and similar tools. Organization restructured to call on both orthos and GPs, giving more coverage and support.

Joe cautioned against calling anything 'normal' in China, dynamic quarter-to-quarter. Great team executing well, well-positioned with local manufacturing, but most competitive market in the world. No specific guidance for China embedded.

John acknowledged execution is required, volume leverage is key. Many changes already made, but productivity gains depend on hitting volume targets. Committed to quarterly updates.

John explicitly stated guidance excludes any VBP impact. Joe noted implementation timing uncertain, Tier 3/4 hospitals affected first (where Align has minimal presence), and 85%+ of China business is private sector.

Joe acknowledged VBP is likely inevitable but has no new details on timing or provinces. Positioning includes ensuring portfolio covers Tier 3/4 city patients.

Joe reframed from 'defending' to 'expanding' the market through technology. John added DSO example showing the playbook works when doctors adopt digital workflows, scanning, visualization, and financing holistically.

John acknowledged both dynamics at play but declined to quantify the split, noting some patients delay due to price sensitivity while doctors put teens in wires/brackets due to economics.

John described three payment paths (direct, doctor financing with extended terms, external like HFD) and emphasized Align is extending favorable payment terms to doctors to support patient conversion.

Joe acknowledged some competitors will be very disadvantaged but hasn't seen material competitive dislocation yet. Focused on executing with own product capability.

Joe acknowledged processing fee friction was real and caused pushback from doctors in Europe and US. Removing it simplifies the sales conversation and refocuses on driving the business forward.

Bryan confirmed longstanding inbound interest and framed the separation as unlocking value via faster autonomous-coding investment; said the process is early.

CFO noted ERP cutovers are for separation, not immediate OpEx benefit; Transform for Future will leverage completed systems for savings going forward. OpEx expected to step down from Q1 into remaining quarters.

CEO confirmed mainly new products with some relaunches; steady cadence across both years (not back-loaded); span all businesses with focus on growth drivers; portfolio of singles/doubles/triples reduces risk.

CFO provided detailed Q1 modeling: 180bps tough comp puts Q1 organic near 1%; operating margins lowest of year; remainder of year more consistent with IPSS Q1/Q3 trade-off dynamic.

CEO highlighted ~20 new products over 2 years (half in MedSurg, rest split HIS/Dental); mostly in growth drivers; combined with underpenetrated existing brands and commercial enhancements.

CFO maintained wide range given dynamic tariff environment; CEO noted even if things change, there would be very little impact to current year.

CEO expressed strong confidence in dental sustainability driven by commercial infrastructure and product cadence; confirmed no extraordinary pricing in quarter.

CFO acknowledged the strong raise but noted multiple variables (separation, tariffs, taxes, FX) that could turn; comfortable with raise given halfway through year.

CEO outlined three levers: specialized commercial teams, leveraging differentiated existing brands, and new product launches. CFO noted normalized 2.5% growth persisting across H1 and expected H2.

CEO confirmed 2.5% beat internal expectations; last time company did 2.5% was 2018. Primarily driven by commercial focus and growth driver specialization.

Management declined segment-level guidance but noted improvements across all four segments from commercial and innovation enhancements.

CFO directly attributed the lower FCF guide to separation costs at ~$130M/quarter run-rate, with step-downs expected in 2026 and 2027.

Ron reaffirmed the $125M exit run rate and flagged the need to normalize for last year's $28M Q3 remeasurement gain, but gave no precise H2 EBIT bridge.

Ron attributed margin improvement to early value creation benefits from more dynamic pricing, continued outperformance of own-brand products, and improved supplier cost negotiations. On oil, said current situation manageable with mitigation plans in place and guidance assumes ability to mitigate rising costs.

Stanley attributed strength to combination of stable-to-positive patient traffic, dentist investment enthusiasm for newer technology, and HSIC's post-cyber sales organization re-energization. Cited data from Henry Schein One claims processing showing modest procedure growth.

Ron confirmed the $200M is a multiyear plan with some benefits expected in 2026 but declined to specify phasing, deferring to 2026 guidance in February. Stanley emphasized sales momentum is back post-cyber with great management throughout.

Stanley described positive July trends with customers returning from cyber-incident losses. Patient traffic remains flat globally but HSIC gaining share. Tariff pass-throughs have stuck, customers shifting to corporate brands where price sensitive.

Stanley outlined two workstreams: gross margin enhancement through pricing, own-brands, and manufacturer partnerships (piloted in Europe 5-6 months ago); and SG&A optimization through global services consolidation and AI. Declined to provide specific dollar targets for the new initiatives.

Stanley noted equipment bookings are in line with pre-COVID backlogs, dentists are investing in practices with digital equipment, DSOs expanding de novo sites, and overall sentiment feels slightly better than general consumer sentiment.

Ron explained sales guidance is largely internally generated with <1pp acquisition growth, FX now expected neutral. On tariffs, clarified that mitigation means financial impact mitigation through sourcing diversification, corporate brands, and supplier negotiations.

Ron provided clear view that market growth is 0-2% with limited price appreciation and minimal acquisition contribution, directly addressing the peer comparison.

Ron acknowledged market growth below Investor Day assumptions but did not break out specific segment organic growth targets. Attributed future EPS leverage to restructuring benefits, market recovery, and pricing.

Pete confirmed no delays from FDA staffing changes on 510(k) submissions. Photon counting CT submission still on track. No downstream impacts from NIH funding concerns observed.

Pete confirmed medium-term targets unchanged. Pathway may differ but margin and growth potential remain. Multiple levers available including local-for-local and dual-supply.